Tesamorelin + Ipamorelin
A popular combination pairing Tesamorelin (FDA-approved for certain conditions) with Ipamorelin to boost growth hormone. Favored for improving body composition, reducing belly fat, and anti-aging. Tesamorelin has proven effectiveness for visceral fat reduction, and Ipamorelin has a clean side-effect profile, making this a premium GH peptide protocol.
Dosage
Tesamorelin 1-2 mg + Ipamorelin 100-300 mcg subcutaneous daily
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (daily)
Get Research-Grade Tesamorelin + Ipamorelin
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Visceral Fat Targeting
Tesamorelin's proven visceral fat reduction amplified by synergistic GH elevation.
Body Composition
Premium GH protocol combining FDA-approved GHRH with selective GHRP.
Mechanism of Action
The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.
Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.
The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.
Regulatory Status
Tesamorelin is FDA approved (Egrifta) for HIV-associated lipodystrophy. Ipamorelin is not FDA approved. The combination is prescribed off-label through compounding pharmacies.
Risks & Safety
Common
injection site reactions (redness, pain), joint pain, swelling in arms and legs, tingling sensations, headache.
Serious
may worsen blood sugar control from sustained GH elevation, may promote existing tumors.
Rare
carpal tunnel syndrome, severe allergic reaction. Not safe during pregnancy or active cancer.
Compare Tesamorelin + Ipamorelin With
Research Papers
2Published: December 31, 2025
AI Summary
A broad review explains how growth hormone secretagogues like tesamorelin and ipamorelin support tissue repair, inflammation control, and nerve recovery in musculoskeletal care. While animal studies look promising, human clinical trials are still lacking.
Published: December 31, 2025
AI Summary
A primer for orthopaedic surgeons on injectable therapeutic peptides, given the growing market and patient interest. The paper emphasizes the need to understand current evidence before recommending these compounds.
Frequently Asked Questions
What is Tesamorelin + Ipamorelin?
A popular combination pairing Tesamorelin (FDA-approved for certain conditions) with Ipamorelin to boost growth hormone. Favored for improving body composition, reducing belly fat, and anti-aging. Tesamorelin has proven effectiveness for visceral fat reduction, and Ipamorelin has a clean side-effect profile, making this a premium GH peptide protocol.
What is Tesamorelin + Ipamorelin used for?
A popular combination pairing Tesamorelin (FDA-approved for certain conditions) with Ipamorelin to boost growth hormone. Favored for improving body composition, reducing belly fat, and anti-aging. Tesamorelin has proven effectiveness for visceral fat reduction, and Ipamorelin has a clean side-effect profile, making this a premium GH peptide protocol.
What is the dosage for Tesamorelin + Ipamorelin?
Standard: Tesamorelin 1-2 mg + Ipamorelin 100-300 mcg subcutaneous once daily, typically before bed. Often cycled 12 weeks on, 4 weeks off.
What are the side effects of Tesamorelin + Ipamorelin?
Common: injection site reactions (redness, pain), joint pain, swelling in arms and legs, tingling sensations, headache. Serious: may worsen blood sugar control from sustained GH elevation, may promote existing tumors. Rare: carpal tunnel syndrome, severe allergic reaction. Not safe during pregnancy or active cancer.
How does Tesamorelin + Ipamorelin work?
The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition. Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination. The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.
How is Tesamorelin + Ipamorelin administered?
Tesamorelin + Ipamorelin is administered via subcutaneous injection (daily).
What is the half-life of Tesamorelin + Ipamorelin?
The half-life of Tesamorelin + Ipamorelin is Tesamorelin: 26 minutes | Ipamorelin: 2 hours.
Is Tesamorelin + Ipamorelin legal?
Tesamorelin is FDA approved (Egrifta) for HIV-associated lipodystrophy. Ipamorelin is not FDA approved. The combination is prescribed off-label through compounding pharmacies.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.